{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:24Z","timestamp":1791305904998,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40258-017-0318-x","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T13:18:51Z","timestamp":1489411131000},"page":"583-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Erin","family":"Vernon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-3829","authenticated-orcid":false,"given":"Bridget","family":"Hiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie H.","family":"Bowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"key":"318_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beem.2012.11.004","volume":"27","author":"S Christin-Maitre","year":"2013","unstructured":"Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27:3\u201312.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"318_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beem.2013.01.001","volume":"27","author":"S Christin-Maitre","year":"2013","unstructured":"Christin-Maitre S. Preface: what should be known about oral contraceptive drugs. Best Pract Res Clin Endocrinol Metab. 2013;27:1\u20132.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"318_CR3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/humrep\/det023","volume":"28","author":"EM Mikkelsen","year":"2013","unstructured":"Mikkelsen EM, Riis AH, Wise LA, Hatch EE, Rothman KJ, S\u00f8rensen HT. Pre-gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort study. Hum Reprod. 2013;28(5):1398\u2013405.","journal-title":"Hum Reprod"},{"key":"318_CR4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2016.03.025","volume":"141","author":"I Martinelli","year":"2016","unstructured":"Martinelli I, Maino A, Abbattista M, et al. Duration of oral contraceptive use and the risk of venous thromboembolism: a case\u2013control study. Throm Res. 2016;141:153\u20137.","journal-title":"Throm Res"},{"issue":"4","key":"318_CR5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/340778","volume":"110","author":"C Goldin","year":"2002","unstructured":"Goldin C, Katz LF. The power of the pill: oral contraceptives and women\u2019s career and marriage decisions. J Polit Econ. 2002;110(4):730\u201370.","journal-title":"J Polit Econ"},{"issue":"4","key":"318_CR6","first-page":"1","volume":"65","author":"Centers for Disease Control and Prevention (CDC).","year":"2016","unstructured":"Centers for Disease Control and Prevention (CDC). U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep Morb Mortal Wkly Rep. 2016;65(4):1\u201366.","journal-title":"MMWR Recomm Rep Morb Mortal Wkly Rep."},{"issue":"10","key":"318_CR7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archinte.162.10.1144","volume":"162","author":"SR Kahn","year":"2002","unstructured":"Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002;162(10):1144\u20138.","journal-title":"Arch Intern Med"},{"key":"318_CR8","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","volume":"111","author":"MA Crowther","year":"2008","unstructured":"Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111:4871\u20139. doi: 10.1182\/blood-2007-10-120543 .","journal-title":"Blood"},{"issue":"4","key":"318_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x\/full","volume":"4","author":"S Schulman","year":"2006","unstructured":"Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10\u00a0years after the first episode of venous thromboembolism treated with warfarin for 6\u00a0weeks or 6 months. J Thromb Haemost. 2006;4(4):734\u201342. doi: 10.1111\/j.1538-7836.2006.01795.x\/full .","journal-title":"J Thromb Haemost"},{"issue":"1","key":"318_CR10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ije\/21.1.48","volume":"21","author":"M Thorogood","year":"1992","unstructured":"Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case\u2013control study. Int J Epidemiol. 1992;21(1):48\u201352.","journal-title":"Int J Epidemiol"},{"issue":"8935","key":"318_CR11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","volume":"344","author":"JP Vandenbroucke","year":"1994","unstructured":"Vandenbroucke JP, Koster T, Bri\u00ebt E, Reitsma PhW, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453\u20137.","journal-title":"Lancet"},{"issue":"1","key":"318_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","volume":"13","author":"JL Kujovich","year":"2011","unstructured":"Kujovich JL. Factor v Leiden thrombophilia. Genet Med. 2011;13(1):1\u201316. doi: 10.1097\/GIM.0b013e3181faa0f2 .","journal-title":"Genet Med"},{"issue":"1","key":"318_CR13","doi-asserted-by":"publisher","first-page":"e2011054","DOI":"10.4084\/MJHID.2011.054","volume":"3","author":"M Jadaon","year":"2011","unstructured":"Jadaon M. Epidemiology of prothrombin G20210A mutation in the Mediterranean region. Mediterr J Hematol Infect Dis. 2011;3(1):e2011054. doi: 10.4084\/MJHID.2011.054 .","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"7","key":"318_CR14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2012-06-430678","volume":"120","author":"A Bruce","year":"2012","unstructured":"Bruce A, Massicotte MP. Thrombophilia screening: whom to test? Blood. 2012;120(7):1353\u20135. doi: 10.1182\/blood-2012-06-430678 .","journal-title":"Blood"},{"key":"318_CR15","unstructured":"World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. http:\/\/apps.who.int\/iris\/bitstream\/10665\/181468\/1\/9789241549158_eng.pdf?ua=1 . Accessed 26 Jan 2016."},{"key":"318_CR16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2005.05715.x","volume":"131","author":"O Wu","year":"2005","unstructured":"Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: a meta analysis and cost-effectiveness analysis. Br J Haematol. 2005;131:80\u201390.","journal-title":"Br J Haematol"},{"key":"318_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00125817-200103000-00009","volume":"3","author":"WW Grody","year":"2001","unstructured":"Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3:139\u201348.","journal-title":"Genet Med"},{"key":"318_CR18","unstructured":"Centers for Disease Control. US medical eligibility criteria (US MEC) for contraceptive use, 2010. http:\/\/www.cdc.gov\/reproductivehealth\/UnintendedPregnancy\/USMEC.htm . Accessed 10 June 2016."},{"issue":"10","key":"318_CR19","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1111\/jth.13411","volume":"14","author":"SK Breakkan","year":"2016","unstructured":"Breakkan SK, Grosse SD, Okoroh EM, et al. Venous thromboembolism and subsequent permanent work-related disability. J Thromb Haemost. 2016;14(10):1978\u201387. doi: 10.1111\/jth.13411 .","journal-title":"J Thromb Haemost"},{"key":"318_CR20","volume-title":"The surgeon general\u2019s call to action to prevent deep vein thrombosis and pulmonary embolism","author":"US Public Health Services","year":"2008","unstructured":"US Public Health Services. The surgeon general\u2019s call to action to prevent deep vein thrombosis and pulmonary embolism. Washington, DC: Office of the Surgeon General; 2008."},{"issue":"10","key":"318_CR21","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2352-3026(15)00202-1","volume":"2","author":"The Lancet Haematology","year":"2015","unstructured":"The Lancet Haematology. Thromboembolism: an under appreciated cause of death (editorial). Lancet Haematol. 2015;2(10):e393.","journal-title":"Lancet Haematol"},{"key":"318_CR22","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W-65.","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"318_CR23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","volume":"1","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ, Sullivan SD, Neumann PJ, Chiou C, Henning J, Wade S, Hay J. Examining the value and quality of health economic analyses (implications of utilizing the QHES). J Manag Care Pharm. 2003;1:53\u201361.","journal-title":"J Manag Care Pharm"},{"key":"318_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","volume":"41","author":"C Chiou","year":"2003","unstructured":"Chiou C, Hay J, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32\u201344.","journal-title":"Med Care"},{"key":"318_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16:231\u201350. doi: 10.1016\/j.jval.2013.02.002 .","journal-title":"Value Health"},{"issue":"8","key":"318_CR26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-016-0397-9","volume":"34","author":"CO Plumpton","year":"2016","unstructured":"Plumpton CO, Roberts D, Pirmohamed M, Hughes DA. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. Pharmacoeconomics. 2016;34(8):771\u201393.","journal-title":"Pharmacoeconomics."},{"issue":"2","key":"318_CR27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jval.2013.05.003","volume":"16","author":"A Compagni","year":"2013","unstructured":"Compagni A, Melegaro A, Tarricone R. Genetic screening for the predisposition to venousembolism: a cost-utility analysis of clinical practice in the italian health care system. Value Health. 2013;16(2):909\u201321.","journal-title":"Value Health"},{"issue":"3","key":"318_CR28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1160\/TH08-03-0149","volume":"100","author":"KJ Smith","year":"2008","unstructured":"Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thromb Haemost. 2008;100(3):447\u201352.","journal-title":"Thromb Haemost"},{"issue":"112","key":"318_CR29","first-page":"358","volume":"1999","author":"Kalev M, Day T, Van de Water N, Ockelford P","year":"1096","unstructured":"Kalev M, Day T, Van de Water N, Ockelford P. Screening for a prothrombotic diathesis in patients attending family planning clinics. N Z Med J. 1096;1999(112):358\u201361.","journal-title":"N Z Med J"},{"issue":"2","key":"318_CR30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0002-9378(97)70498-8","volume":"176","author":"A Alt\u00e8s","year":"1997","unstructured":"Alt\u00e8s A, Souto JC, Mateo J, Borrell M, Fontcuberta J. Activated protein C resistance assay when applied in the general population. Am J Obstet Gynecol. 1997;176(2):358\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"318_CR31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0010-7824(99)00033-5","volume":"59","author":"G Palareti","year":"1999","unstructured":"Palareti G, Legnani C, Frascaro M, et al. Screening for activated protein C resistance before oral contraceptive treatment: a pilot study. Contraception. 1999;59(5):293\u20139.","journal-title":"Contraception"},{"issue":"4","key":"318_CR32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0015-0282(99)00318-0","volume":"72","author":"MD Creinin","year":"1999","unstructured":"Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril. 1999;72(4):646\u201351.","journal-title":"Fertil Steril"},{"key":"318_CR33","unstructured":"NextDxGx: the genetic testing resource. https:\/\/www.nextgxdx.com\/ . Accessed 28 July 2016."},{"key":"318_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.thromres.2015.11.009","volume":"137","author":"T Delate","year":"2016","unstructured":"Delate T, Hsiao W, Kim B, et al. Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism. Throm Res. 2016;137:97\u2013102. doi: 10.1016\/j.thromres.2015.11.009 .","journal-title":"Throm Res"},{"issue":"4","key":"318_CR35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.2009.07786.x","volume":"146","author":"LN Roberts","year":"2009","unstructured":"Roberts LN, Patel RK, Arya R. Venous thromboembolism and ethnicity. Br J Haematol. 2009;146(4):369\u201383.","journal-title":"Br J Haematol"},{"issue":"3","key":"318_CR36","first-page":"809","volume":"86","author":"J Emmerich","year":"2001","unstructured":"Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost. 2001;86(3):809\u201316.","journal-title":"Thromb Haemost"},{"issue":"2","key":"318_CR37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1542\/peds.2010-2221","volume":"127","author":"CC Trenor","year":"2011","unstructured":"Trenor CC, Chung RJ, Michelson AD, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347\u201357.","journal-title":"Pediatrics"},{"key":"318_CR38","first-page":"520","volume":"75","author":"FR Rosendaal","year":"1996","unstructured":"Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost. 1996;75:520\u20136.","journal-title":"Thromb Haemost"},{"key":"318_CR39","doi-asserted-by":"publisher","unstructured":"American Congress of Obstetricians and Gynecologists Committee opinion no 577: understanding and using the U.S. selected practice recommendations for contraceptive use, 2013. Obstet Gynecol. 2013;122(5):1132\u20133. doi: 10.1097\/01.AOG.0000437383.81092.4e .","DOI":"10.1097\/01.AOG.0000437383.81092.4e"},{"issue":"1","key":"318_CR40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.160.1.49","volume":"160","author":"KWM Bloemenkamp","year":"2000","unstructured":"Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting disorders. Arch Intern Med. 2000;160(1):49\u201352.","journal-title":"Arch Intern Med"},{"key":"318_CR41","doi-asserted-by":"publisher","first-page":"b2921","DOI":"10.1136\/bmj.b2921","volume":"339","author":"Vlieg A Hylckama van","year":"2009","unstructured":"van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case\u2013control study. BMJ. 2009;339:b2921. doi: 10.1136\/bmj.b2921 .","journal-title":"BMJ"},{"key":"318_CR42","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","volume":"339","author":"\u00d8 Lidegaard","year":"2009","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.","journal-title":"BMJ"},{"issue":"15","key":"318_CR43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0268355515569424","volume":"30","author":"DD Myers","year":"2015","unstructured":"Myers DD. Pathophysiology of venous thrombosis. Phlebology. 2015;30(15):7\u201313.","journal-title":"Phlebology"},{"issue":"4","key":"318_CR44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1524-4733.2007.00175.x","volume":"10","author":"T Hoomans","year":"2007","unstructured":"Hoomans T, Evers SMAA, Ament AJHA, et al. The methodological quality of economic evaluations of guideline implementation into clinical practice: a systematic review of empiric studies. Value Health. 2007;10(4):305\u201316.","journal-title":"Value Health"},{"key":"318_CR45","doi-asserted-by":"crossref","unstructured":"Lidegaard \u00d8. COCs and VTE risks. (Electronic discussion of Lidegaard \u00d8, L\u00f8kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890). BMJ. 2009. http:\/\/www.bmj.com\/content\/339\/bmj.b2890\/rapid-responses .","DOI":"10.1136\/bmj.b2890"},{"issue":"3","key":"318_CR46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jmv.2009.02.005","volume":"34","author":"G Pernod","year":"2009","unstructured":"Pernod G, Biron-Andreani C, Morange PE, et al. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc. 2009;34(3):156\u2013203.","journal-title":"J Mal Vasc."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-017-0318-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-017-0318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-017-0318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T01:31:52Z","timestamp":1658799112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-017-0318-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s40258-017-0318-x","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,13]]}}}